Skip to main content


Buy Article:

$46.00 + tax (Refund Policy)

Respirable beryllium is a potent toxicant that can cause pulmonary granulomas and inflammation in exposed individuals. These effects, known as chronic beryllium disease (CBD), occurred in 1–3% of all beryllium workers and in 4–11% of beryllium machinists and ceramics workers in recent investigations. Decades ago, Merril Eisenbud and his colleagues conducted early epidemiologic research to improve the understanding of CBD risks at low levels of beryllium exposure. Today, CBD continues to pose a challenge to industrial hygienists, toxicologists, and other health professionals and researchers seeking to understand and mitigate this difficult to treat but clearly preventable disease. We discuss current approaches for assessing and managing CBD risk, and highlight current research efforts that may improve our understanding of CBD. Special emphasis is given to the role of genetics in CBD development, the use of immunologically based lymphocyte proliferation testing (LPT) in occupational health surveillance and risk management, and the social, legal, and ethical challenges posed by this information in forming appropriate preventive strategies.

Keywords: Berylliosis; Chronic beryllium disease (CBD); Lymphocyte proliferation testing (LPT); Occupational health; Polymorphism

Document Type: Research Article

Publication date: January 1, 2000

More about this publication?
  • The journal Technology is a forum for presentation of information encompassing essentially the entire field of applied sciences. Owing to the broad nature of applied sciences, authors should be guided by the interest of the readers who are likely to be knowledgeable non-specialists.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content